Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.

Gynecologic oncology - 1 Mar 2025

Alvero Ayesha B, Wu Sharon, Farrell Alex, Kim Seongho, Wallbillich John J, Winer Ira, Morris Robert, Spetzler David, Anderson Matthew L, Puccini Alberto, Jones Nathaniel L, Herzog Thomas J, Thaker Premal H, Mor Gil, Gogoi Radhika P

Abstract excerpt

OBJECTIVE: The purpose of this study was to evaluate the transcriptomic profile of BRCA1 mutant (BRCA1mut) and BRCA2 mutant (BRCA2mut) HGSOC compared to homologous recombination wild-type (HRwt) tumors utilizing the CARIS database. METHODS: Next-generation and Whole Transcriptome Sequencing (WTS; Caris Life Sciences, Phoenix, AZ) was performed on a total of 2745 HGSOC tumor samples. BRCA mutations were defined as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Transcriptome

Source

Identifiers

PMID: 39970633
DOI: 10.1016/j.ygyno.2025.02.010

Genes

BRCA1
BRCA2
PIK3CA
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.PMID 39970633Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.Semantic proximity Read ↗

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.Semantic proximity Read ↗

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.Semantic proximity Read ↗

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read ↗

Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processesSemantic proximity Read ↗

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaSemantic proximity Read ↗

High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity Read ↗

Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profilingSemantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancerSemantic proximity Read ↗

Concurrent RB1 loss and<i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.